home / stock / heb / heb news

HEB News and Press, Hemispherx BioPharma Inc. From 04/01/19

Stock Information
Company Name: Hemispherx BioPharma Inc.
Stock Symbol: HEB
Market: NYSE
Website: hemispherx.net
Menu
HEB HEB Quote HEB Short HEB News HEB Articles HEB Message Board
Get HEB Alerts

News, Short Squeeze, Breakout and More Instantly...
HEB - Hemispherx Biopharma reports FY results

Hemispherx Biopharma (NYSEMKT: HEB ): FY GAAP EPS of -$0.22. More news on: Hemispherx Biopharma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

HEB - Hemispherx Reports 2018 Year-end Financial Results

OCALA, Fla., April 01, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announces financial results for the fiscal year ended December 31, 2018, and provides a business update. Highlights of 2018 included: Publication of a non-clinical study showing Ampligen ...

HEB - Hemispherx Bio up 8% on Ampligen progress

Nano cap Hemispherx Biopharma ( HEB +7.5% ) is up on more than triple normal volume following its update on its Ampligen programs. It plans to release additional updates on a quarterly basis. More news on: Hemispherx Biopharma, Inc., Merck & Co., Inc., Healthcare stocks news, ...

HEB - Hemispherx Biopharma Announces Significant Progress in its Ampligen Pancreatic Cancer Program and Multiple Ampligen+Checkpoint Blockade Immuno-Oncology Programs

OCALA, Fla., March 13, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D company focused on unmet medical needs in immunology, announced today the first of a series of planned quart...
HEB - Hemispherx Biopharma Announces $5.3 Million in Expected Gross Proceeds from Recently Expired Rights Offering

OCALA, Fla., March 06, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, announced today that t...

HEB - Hemispherx Announces Dutch Health Inspectorate Approval to Extend the Ampligen Pancreatic Cancer Early Access Program Until March 2020

OCALA, Fla., Feb. 28, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, announced today the extension of its Early Access Pro...

HEB - Hemispherx Biopharma Announces Extension of Rights Offering Period to March 5, 2019

OCALA, Fla., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, announced today that it...
HEB - Hemispherx Biopharma Updates the Terms of Previously Announced Rights Offering and Announces Senior Management and Directors All Plan to Participate in the Offering

OCALA, Fla., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, today announced that it...

HEB - Hemispherx Biopharma Announces Commencement of Rights Offering Subscription Period

OCALA, Fla., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, today announced that th...

HEB - Hemispherx Biopharma Reminds Investors of Today's Deadline to be a Stockholder of Record

To be a stockholder of record, investors are advised to own Hemispherx stock by 4:00 PM ET, Tuesday, February 12, 2019 to account for T+2 settlement timing Record date established as Thursday, February 14, 2019 OCALA, Fla., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, I...
Previous 10 Next 10